Adial Pharmaceuticals (ADIL) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADIL shares.
View ADIL analyst ratings or view top-rated stocks.

Adial Pharmaceuticals' stock was trading at $5.3750 at the start of the year. Since then, ADIL stock has decreased by 53.1% and is now trading at $2.52.
View the best growth stocks for 2023 here.

Adial Pharmaceuticals saw a decline in short interest in August. As of August 31st, there was short interest totaling 64,600 shares, a decline of 12.6% from the August 15th total of 73,900 shares. Based on an average daily trading volume, of 131,100 shares, the days-to-cover ratio is presently 0.5 days. Approximately 6.2% of the shares of the stock are short sold.
View Adial Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ADIL earnings forecast.

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) posted its earnings results on Monday, August, 21st. The company reported ($1.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.50) by $0.17.

Adial Pharmaceuticals's stock reverse split before market open on Monday, August 7th 2023. The 1-25 reverse split was announced on Monday, August 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Aytu BioPharma (AYTU), T2 Biosystems (TTOO), AIM ImmunoTech (AIM), Tandem Diabetes Care (TNDM), vTv Therapeutics (VTVT), Acasti Pharma (ACST) and Adamis Pharmaceuticals (ADMP).

(ADIL) raised $8 million in an IPO on Friday, July 27th 2018. The company issued 1,500,000 shares at $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager.

Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."

Adial Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.20%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Bankole A Johnson, James W Jr Newman and William B Stilley III.
View institutional ownership trends.

Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADIL stock can currently be purchased for approximately $2.52.

Adial Pharmaceuticals (NASDAQ:ADIL) has a market capitalization of $3.07 million. The company earns $-12,730,000.00 in net income (profit) each year or ($7.54) on an earnings per share basis.

Adial Pharmaceuticals' mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The official website for the company is www.adialpharma.com. The company can be reached via phone at (434) 422-9800 or via email at investor_relations@haynesintl.com.